---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-173983"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2023-06-23T23:59:59+00:00"
generated_at: "2026-06-13T18:16:41.693502+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Taysha stockholders approve reverse stock split and authorized share reduction

## Summary
- Reverse stock split authorized with ratio range of 1:5 to 1:20; 43.1M for, 10.5M against.
- Authorized shares reduction (formula based on split ratio) approved: 43.3M for, 10.2M against.
- Both directors elected: Sean P. Nolan (35.6M for) and Laura Sepp-Lorenzino (33.6M for).
- Ratification of Deloitte as auditor: 53.5M for, 51k against.
- Broker non-votes of 14.3M on director elections; no broker non-votes on other proposals.

## SEC filing metadata
- accession: 0001193125-23-173983
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2023-06-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312523173983/0001193125-23-173983-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312523173983/d242570d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-173983
- JSON: https://secwatch.observer/filing/0001193125-23-173983.json
- Plain text: https://secwatch.observer/filing/0001193125-23-173983.txt

## Key facts
- Shareholder Votes
  Taysha Gene Therapies, Inc. shareholders approved Approval to adopt a series of alternate amendments to the Company's Certificate of Incorporation to effect an authorized shares reduction, with specific number of authorized shares determined by formula based on ratio utilized for reverse stock split at the 2023-06-22 meeting.
  - Proposal: charter amendment
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: Proposal No. 4: Approval to adopt a series of alternate amendments to the Company's Certificate of Incorporation to effect an authorized shares reduction, with the specific number of authorized shares determined by a formula that is based on the ratio utilized for a reverse stock split. The votes were cast as follows: Votes For Votes Against Abstained Amendment to effectuate an authorized shares reduction 43,305,340 10,246,833 190,654 Broker Non-Votes: 0.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312523173983/0001193125-23-173983-index.htm
- Shareholder Votes
  Taysha Gene Therapies, Inc. shareholders approved Election of Sean P. Nolan and Laura Sepp-Lorenzino, Ph.D. as directors at the 2023-06-22 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: Proposal No. 1: Election of two nominees to serve as directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Sean P. Nolan 35,556,636 3,890,877 Laura Sepp-Lorenzino, Ph.D. 33,595,590 5,851,923 Broker Non-Votes: 14,295,314. Both nominees were elected.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312523173983/0001193125-23-173983-index.htm
- Shareholder Votes
  Taysha Gene Therapies, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-22 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: Proposal No. 2: Ratification of the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes were cast as follows: Votes For Votes Against Abstained Ratification of appointment of Deloitte & Touche LLP 53,532,998 51,055 158,774 Broker Non-Votes: 0.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312523173983/0001193125-23-173983-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.